Fight­ing a gener­ic on­slaught, No­var­tis adds CAR-T to its grow­ing list of late-stage block­busters

One of the rea­sons why No­var­tis isn’t be­ing forced to bid in­to the stratos­phere for late-stage drugs is that its in­dus­try-top­ping R&D bud­get — $9 bil­lion last year — has al­ready fund­ed one of the biggest late-stage pipelines in the in­dus­try. The phar­ma gi­ant un­der­scored that to­day as it out­lined 13 prospec­tive block­busters with up­com­ing piv­otal read­outs in the com­ing months and years, a group that now in­cludes its lead CAR-T ther­a­py for the very first time. And it added more de­tails on its im­muno-on­col­o­gy strat­e­gy, which has lagged be­hind lead­ers like Mer­ck, Bris­tol-My­ers Squibb and Roche.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.